Neuranics Unleashes 24/7 Heart Monitoring Revolution at CES 2024 with a Wearable Magnetocardiography (MCG) Development Platform

Magnetic sensor specialist startup Neuranics has announced that it will launch a magnetic sensor development kit that will record the magnetic activity of the heart and wirelessly transfer this over Bluetooth for live 24/7 recording and analysis on a smartphone,…

Read MoreNeuranics Unleashes 24/7 Heart Monitoring Revolution at CES 2024 with a Wearable Magnetocardiography (MCG) Development Platform

Blood cancers: AOP Health presents new findings in patients with polycythemia vera to be presented at the American Society of Hematology (ASH) 65th Annual Meeting

AOP Orphan Pharmaceuticals GmbH (AOP Health) has announced the launch of Ropeginterferon alfa-2b in patients with low-risk polycythemia vera (PV). We presented the results of an analysis evaluating the impact of individually optimized dosing regimens on therapeutic efficacy. 1These new data demonstrate…

Read MoreBlood cancers: AOP Health presents new findings in patients with polycythemia vera to be presented at the American Society of Hematology (ASH) 65th Annual Meeting

World-renowned cancer researchers from Spain and the United States join forces to address critical needs and challenges in women’s cancer research

Mary Kay Inc. is the world’s leading direct-selling skin care and color cosmetics brand1 . The company and its sponsored foundations, including the Mary Kay Ash Foundation in the United States, continue to fund various research programs and projects, provide grants to world-renowned scientists, and promote clinical trials.…

Read MoreWorld-renowned cancer researchers from Spain and the United States join forces to address critical needs and challenges in women’s cancer research

Merck Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis

Merck, a leading science and technology company, today announced that its two Phase III EVOLUTION clinical trials (evolutionRMS 1 and evolutionRMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates…

Read MoreMerck Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis

New State-of-the-Art Hybrid Operating Room Unveiled at MarinHealth Medical Center

Today, MarinHealth Medical Center unveiled its new hybrid operating room, a surgical suite that combines the best tools of a traditional operating setting with advanced imaging technology. It offers advanced technology to provide real-time images for guidance during complex cardiovascular and vascular…

Read MoreNew State-of-the-Art Hybrid Operating Room Unveiled at MarinHealth Medical Center

Exscientia receives grant from Open Philanthropy to explore a new therapeutic approach for pandemic influenza

Exscientia plc (Nasdaq: EXAI) today announced that it has received a $2.3 million grant from Open Philanthropy, a multi-program philanthropic funder in the field of global health and well-being. Under this grant, Exscientia intends to use activation of the host response…

Read MoreExscientia receives grant from Open Philanthropy to explore a new therapeutic approach for pandemic influenza

The Chuck Lorre Family Foundation Makes $10 Million Gift To Children’s Hospital Los Angeles To Support Research Education for Underrepresented High School and College Students

The Chuck Lorre Family Foundation Makes $10 Million Gift To Children’s Hospital Los Angeles To Support Research Education for Underrepresented High School and College Students The Chuck Lorre Family Foundation has pledged a total of $10 million to Children’s Hospital Los Angeles to support…

Read MoreThe Chuck Lorre Family Foundation Makes $10 Million Gift To Children’s Hospital Los Angeles To Support Research Education for Underrepresented High School and College Students

CG Oncology Receives Both FDA Fast Track and Breakthrough Therapy Designation for Cretostimogene Grenadenorepvec in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

CG Oncology, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted both Fast Track Designation and Breakthrough Therapy Designation for cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin (BCG)-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ with or without…

Read MoreCG Oncology Receives Both FDA Fast Track and Breakthrough Therapy Designation for Cretostimogene Grenadenorepvec in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer